Literature DB >> 11096463

Hypertensive Crises.

.   

Abstract

Despite the availability of effective antihypertensive agents, hypertensive crises still occur with relative frequency and remain an important therapeutic challenge. Hypertensive crises are defined as an abrupt elevation of blood pressure (BP) to a systolic BP reading of more than 210 mm Hg and a diastolic BP level of more than 120 mm Hg. The most important initial clinical decision is to differentiate between hypertensive urgency and hypertensive emergency. In both cases, therapy should be promptly initiated to prevent any permanent loss of organ function or life. The underlying pathophysiology and the intent to avoid adverse effects should guide the choice of antihypertensive agents. The most important principle to remember is to lower the blood pressure sufficiently to limit end-organ dysfunction, but without necessarily reaching normotensive levels. Additionally, it is always important to assess the fluid status of the patient and reestablish euvolemia as soon as feasible to avoid precipitous falls in blood pressure.

Entities:  

Year:  1999        PMID: 11096463     DOI: 10.1007/s11936-999-0001-0

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  22 in total

1.  Degenerative vascular disease in the Egyptian mummy.

Authors:  A T SANDISON
Journal:  Med Hist       Date:  1962-01       Impact factor: 1.419

2.  Clinical notes on the illness and death of President Franklin D. Roosevelt.

Authors:  H G Bruenn
Journal:  Ann Intern Med       Date:  1970-04       Impact factor: 25.391

3.  Clinical implications of primary aldosteronism with resistant hypertension.

Authors:  E L Bravo; F M Fouad-Tarazi; R C Tarazi; M Pohl; R W Gifford; D G Vidt
Journal:  Hypertension       Date:  1988-02       Impact factor: 10.190

4.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1997-11-24

5.  Renoprotective effects of a combined endothelin type A/type B receptor antagonist in experimental malignant hypertension.

Authors:  M Kohno; K Yokokawa; K Yasunari; H Kano; M Minami; M Ueda; Y Tatsumi; J Yoshikawa
Journal:  Metabolism       Date:  1997-09       Impact factor: 8.694

6.  Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function.

Authors:  N H Shusterman; W J Elliott; W B White
Journal:  Am J Med       Date:  1993-08       Impact factor: 4.965

Review 7.  Renal dopamine receptors in health and hypertension.

Authors:  P A Jose; G M Eisner; R A Felder
Journal:  Pharmacol Ther       Date:  1998-11       Impact factor: 12.310

8.  Three cases of malignant hypertension: the roles of endothelin-1 and the renin-angiotensin-aldosterone system.

Authors:  M Yoshida; H Nonoguchi; A Owada; S Ishiyama; Y Maeda; K Ando; H Iwamoto; T Shiigai; F Marumo; K Tomita
Journal:  Clin Nephrol       Date:  1994-11       Impact factor: 0.975

9.  The acute and long-term ocular effects of accelerated hypertension: a clinical and electrophysiological study.

Authors:  S J Talks; P Good; C G Clough; D G Beevers; P M Dodson
Journal:  Eye (Lond)       Date:  1996       Impact factor: 3.775

10.  The last illness of Herod the Great, king of Judaea.

Authors:  A T Sandison
Journal:  Med Hist       Date:  1967-10       Impact factor: 1.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.